The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
Zacks Investment Research on MSN
J&J wins FDA nod for subcutaneous version of NSCLC drug Rybrevant (revised)
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The latest update is out from Simcere Pharmaceutical Group Limited ( ($HK:2096) ). Simcere Pharmaceutical Group Limited has received approval from ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to ...
J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.
A lifestyle intervention was associated with significant reductions in BMI, urine albumin-to-creatinine ratio and eGFR for ...
Epidermal growth factor receptor (EGFR) is a protein on the surface of your cells that helps them grow. When the gene that codes for EGFR has a mutation, it affects the way this protein works, causing ...
The epidermal growth factor receptor (EGFR)/ERBB family has evolved from a primordial, simple pathway of a single ligand receptor pair to a complex signalling network. Studies in invertebrates and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback